引用文本：王斌, 卫聪慧, 王雪涔, 等. 放射治疗在Lugano ⅠE和ⅡE期胃黏膜相关淋巴组织淋巴瘤患者中的治疗效果[J/CD]. 消化肿瘤杂志（电子版）, 2025, 17(2):213-217.

作者：王斌 ¹，卫聪慧²，王雪涔³，牛绍清³，段超²

单位：1. 滕州市中心人民医院 两腺外科，山东 滕州 277500；2. 滕州市中心人民医院 病理科，山东 滕州 277500；3. 中山大学附属第一医院 放射治疗科，广东 广州 510080

Authors：Wang Bin¹, Wei Conghui², Wang Xuecen³, Niu Shaoqing³, Duan Chao²

Unit：1.Department of Breast and Thyroid Surgery, Tengzhou Central People’s Hospital, Tengzhou 277500, Shangdong, China；2.Department of Pathology, Tengzhou Central People’s Hospital, Tengzhou 277500, Shangdong, China；3.Department of Radiotherapy, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China

摘要：

目的 探讨放射治疗（简称放疗）对于根除幽门螺杆菌（helicobacter pylori，Hp）治疗后复发或者Hp阴性的Lugano Ⅰ_E和Ⅱ_E期胃黏膜相关淋巴组织（mucosa-associated lymphoid tissue，MALT）淋巴瘤患者的治疗效果。方法 本研究为一项回顾性研究，总结了2021年5月至2024年11月在中山大学附属第一医院放射治疗科接受根治性放疗的Lugano Ⅰ_E和Ⅱ_E期胃MALT淋巴瘤患者（n=12）的临床病理资料。所有患者于放疗前均接受Hp状态检查，检测方法为¹³C-尿素呼气试验。放疗均采用容积调强放射治疗，大体肿瘤靶区的中位放疗剂量为3570 cGy（范围：3000~3600 cGy）, 临床靶区的中位放疗剂量为3060 cGy（范围：3000~3060 cGy），每周周一到周五治疗，每天放疗1次，采用常规分割照射（每次180～200 cGy）。采用描述性统计方法分析患者的生存预后。结果 共纳入12例胃MALT淋巴瘤患者，其中Lugano Ⅰ_E期患者10例，Ⅱ_E期患者2例。放疗前的Hp检查结果显示，11例患者为Hp阴性，1例患者为Hp阳性（既往接受过根除Hp治疗）。所有患者的中位随访时间为38.6个月，其3年总生存率和无进展生存率均为100%。末次随访时，11例患者为完全代谢缓解，1例患者为部分代谢缓解。结论 放疗是经根除Hp治疗后复发或者Hp阴性的Lugano Ⅰ_E和Ⅱ_E期胃MALT淋巴瘤患者的有效治疗手段，能取得理想的肿瘤局部控制和远期生存。

关键词：胃黏膜相关淋巴组织淋巴瘤；放疗；幽门螺杆菌；生存预后

Abstract：

Objective To investigate the therapeutic effect of radiotherapy on patients with Lugano stage Ⅰ_E and Ⅱ_E gastric mucosa-associated lymphoid tissue (MALT) lymphoma who experience recurrence after eradication helicobacter pylori (Hp) treatment or who are Hp-negative. Method This is a retrospective study. The clinical and pathological data of gastric MALT lymphoma patients (n=12) with Lugano stage Ⅰ_E and Ⅱ_E who received radical radiotherapy at the Department of Radiotherapy, the First Affiliated Hospital of Sun Yat-sen University from May 2021 to November 2024 were collected. All patients underwent an examination of the Hp status before radiotherapy, and the detection method was the carbon-13 urea breath test. All patients received radical radiotherapy using volumetric modulated arc therapy. The median radiotherapy dose for the gross tumor volume was 3570 cGy (range: 3000-3600 cGy), and the median radiotherapy dose for the clinical target volume was 3060 cGy (range: 3000-3060 cGy). The treatment was carried out from Monday to Friday every week with radiotherapy administered once a day and conventional fractionated irradiation was adopted (180-200 cGy per fraction). Descriptive statistical analysis was used to analyze the survival prognosis of patients. Result A total of 12 patients with gastric MALT lymphoma were included, and 10 patients with Lugano stage Ⅰ_E and 2 patients with stage Ⅱ_E. The result of test for Hp before receiving radiotherapy showed that, 11 patients were Hp-negative, while 1 patient was Hp-positive (received Hp eradication treatment before). The median follow-up time was 38.6 months, and the 3-year overall survival rates and progression-free survival rates were both 100%. At the last follow-up, 11 patients achieved complete metabolic response and 1 patient achieved partial metabolic response. Conclusion Radiotherapy is an effective treatment method for gastric MALT lymphoma patients with Lugano stage Ⅰ_E and Ⅱ_E who experience recurrence after eradication Hp treatment or who are Hp-negative. Radiotherapy can achieve ideal local tumor control and long-term survival.

Key words：Gastric mucosa-associated lymphoid tissue lymphoma; Radiotherapy; Helicobacter pylori; Survival prognosis

注：网络优先发布